<DOC>
	<DOCNO>NCT00229723</DOCNO>
	<brief_summary>The primary purpose study assess effectiveness ZD1839 250 mg 500 mg give either concomitantly maintenance standard therapy radiotherapy ( X-rays ) plus chemotherapy ( cisplatin ) term local disease control ( progression-free ) rate 2 year .</brief_summary>
	<brief_title>IRESSAâ„¢ ( Gefitinib ) With Cisplatin Plus Radiotherapy Treatment Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm stage III IVA squamous cell carcinoma head neck No prior surgery chemotherapy/biological therapy/radiation therapy Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) Life expectancy 12 week Cancers nasal space , oral cavity larynx ; certain lung disease . Abnormal blood chemistry ; uncontrolled respiratory , cardiac , hepatic , renal disease ; coexist malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Head Neck Squamous Cell Carcinoma</keyword>
	<keyword>Head Neck Squamous Cell Cancer</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Squamous Cell Cancer</keyword>
</DOC>